There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Wave Life Sciences (WVE – Research Report), Femasys (FEMY – Research Report) and ImmunoGen (IMGN – Research Report) with bullish sentiments.
Wave Life Sciences (WVE)
In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Wave Life Sciences, with a price target of $8.00. The company’s shares closed last Thursday at $5.74.
According to TipRanks.com, Fein is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Wave Life Sciences is a Strong Buy with an average price target of $9.40, implying a 79.0% upside from current levels. In a report released yesterday, Mizuho Securities also maintained a Buy rating on the stock with a $10.00 price target.
See the top stocks recommended by analysts >>
Femasys (FEMY)
In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Femasys, with a price target of $13.00. The company’s shares closed last Thursday at $1.52.
According to TipRanks.com, Bodnar has 0 stars on 0-5 stars ranking scale with an average return of
Femasys has an analyst consensus of Strong Buy, with a price target consensus of $10.00, representing an 825.9% upside. In a report issued on September 26, JonesTrading also maintained a Buy rating on the stock with a $7.00 price target.
ImmunoGen (IMGN)
In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on ImmunoGen, with a price target of $27.00. The company’s shares closed last Thursday at $16.00.
According to TipRanks.com, Ramakanth is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for ImmunoGen with a $24.86 average price target, which is a 62.4% upside from current levels. In a report issued on September 22, Piper Sandler also maintained a Buy rating on the stock with a $24.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on WVE:
- Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D Day
- Wave Life Sciences to Present at the Chardan 7th Annual Genetic Medicines Conference
- Wave Life Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-006, the First-ever RNA Editing Clinical Candidate, and Plans for Upcoming Virtual “R&D Day”
- Wave Life Sciences submits first clinical application for RNA editing candidate
